antisense therapy

(redirected from Antisense drugs)

an·ti·sense ther·a·py

use of antisense DNA for the inhibition of transcription or translation of a specific gene or gene product for therapeutic purposes.
References in periodicals archive ?
The company added that ISIS-SOD1Rx is part of its strategic collaboration with Biogen to discover and develop antisense drugs to treat neurological diseases, including ALS, a rare, fatal neurodegenerative disorder.
Isis Pharmaceuticals, a company involved in the discovery and growth of antisense drugs using novel drug discovery platform, announced that it has gained a $3 million milestone payment from GlaxoSmithKline (GSK) concerning to start up of a natural history study, which will support the advancement of one of the alliance programmes.
The patent claims broadly cover antisense drugs with "chimeric" or "gapmer" structures, including Isis' proprietary second-generation structures and the compositions of numerous other antisense compounds.
AVI BioPharma develops therapeutic products for the treatment of life-threatening diseases using third-generation NEUGENE(R) antisense drugs.
Isis and Lilly will continue to advance antisense drugs identified during the previous collaboration, and continue their efforts to develop and refine antisense technologies.
Inhalation could be used as the entrance of antisense drugs into the body.
The promise of antisense drugs lies in the theory that they work on a specific target disease without causing significant side effects.
This alliance combines Isis' expertise in antisense technology to evaluate potential neurological targets and discover antisense drugs with Biogen's capability to develop therapies for neurological disorders.
Second-generation antisense drugs offer greater potency, enhanced tolerability, and improved dosing convenience compared to first-generation antisense drugs.
Antisense drugs are short, chemically-modified RNA-like and DNA-like molecules that scientists design to complement a small, specific segment of messenger RNA.
a San Diego-based biotechnology company, to develop so-called antisense drugs to block the activity of bcl-2.